NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease

Cancer Causes and Control

Volumn 11, Issue 3, 2000, Pages 249-255

  Coogan, Patricia F ^a   Rosenberg, Lynn ^a   Louik, Carol ^a   Zauber, Ann G ^b   Stolley, Paul D ^c   Strom, Brian L ^d   Shapiro, Samuel ^a  

^a BOSTON UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Case control studies; Colorectal neoplasms; Family characteristics; NSAIDs

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; CASE CONTROL STUDY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HUMAN; MALE; NOTE; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; ODDS RATIO; QUESTIONNAIRES; RISK FACTORS;

EID: 0034124321     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008931708716     Document Type: Note

References (30)

1. 1. Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 90: 1609-1620.
2. 2. Pollard M, Luckert PH (1984) Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Lett 25: 117-121.
3. 3. Metzger U, Meier J, Uhlschmid G, Weihe H (1984) Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis Colon Rectum 27: 366-369.
4. 4. Reddy BS, Nayini J, Tokumo R, Rigotty J, Zang E, Kelloff G (1990) Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with D,L-alpha-difluoromethylorithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 50: 2562-2568.
5. 5. Boolbol SK, Dannenberg AJ, Chaburn A, et al. (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 2: 556-560.
6. 6. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 83: 355-358.
7. 7. Rosenberg L, Louik C, Shapiro S (1998) Nonsteroidal anti-flammatory drug use and reduced risk of large bowel carcinoma. Cancer 82: 2326-2333.
8. 8. Suh O, Mettlin C, Petrelli NJ (1993) Aspirin use, cancer, and polyps of the large bowel. Cancer 72: 1171-1177.
9. 9. Giovannucci E, Rim EB, Stampfer MJ, Colditz A, Ascherio A, Willett WC (1994) Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Intern Med 121: 241-246.
10. 10. Giovannucci E, Egan K, Hunter DJ, et al. (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333: 609-614.
11. 11. Thun MJ, Namboordi MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596.
12. 12. Marcus AJ (1995) Aspirin as prophylaxis against colorectal cancer. [Editorial]. N Engl J Med 333: 656-658.
13. 13. Potter JD, Slattery ML, Bostick RM, Gapstur SM (1993) Colon cancer: a review of the epidemiology. Epidemiol Rev 15: 499-545.
14. 14. Peipins LA, Sandler RS (1994) Epidemiology of colorectal adenomas. Epidemiol Rev 16: 273-297.
15. 15. Houlston RS, Collins A, Slack J, Morton NE (1992) Dominant genes for colorectal cancer are not rare. Ann Hum Genet 56: 99-103.
16. 16. Shapiro S (1994) Case-control surveillance. In: Strom BL, ed. Pharmacoepidemiology, 2nd edn. Chichester, UK: John Wiley and Sons, pp. 301-322.
17. 17. Ruschoff J, Wallinger S, Dietmaier W, et al. (1998) Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci USA 95: 11301-11306.
18. 18. Karnes WE Jr, Shattuck-Brandt R, Burgard LJ, et al. (1998) Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 58: 5473-5477.
19. 19. Labayle D, Fischer D, Vielh P, et al. (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635-639.
20. 20. Giardiello FM, Hamilton SR, Krush AJ, et al. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316.
21. 21. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK (1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80: 1618-1619.
22. 22. Hixson LJ, Earnest DL, Fenerty B, Sampliner RE (1993) NSAID effect on sporadic colon polyps. Am J Gastroenterol 88: 1652-1656.
23. 23. Ladenheim J, Garcia G, Titzer D, et al. (1995) Effect of sulindac on sporadic colonic polyps. Gastroenterology 108: 1083-1087.
24. 24. Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Oka T (1997) Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 40: 344-349.
25. 25. Aaltonen LA, Peltomaki P, Leach FS, et al. (1993) Clues to the pathogenesis of familial colorectal cancer. Science 260: 812-816.
26. 26. Petersen GM (1995) Genetic epidemiology of colorectal cancer. Eur J Cancer 31A: 1047-1050.
27. 27. Scapoli C, Ponz de Leon M, Sassatelli R, et al. (1994) Genetic epidemiology of hereditary non-polyposis colorectal cancer syndromes in Modena, Italy: results of a complex segregation analysis. Ann Hum Genet 58: 275-295.
28. 28. Aarnio M, Sankila R, Pukkala E, et al. (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81: 214-218.
29. 29. Potter JD (1999) Colorectal cancer: molecules and populations. J Natl Cancer Inst 91: 916-932.
30. 30. Anonymous (1999) Early trials probe COX-2 inhibitors' cancer-fighting potential. [News] J Natl Cancer Inst 14: 1186-1187.